Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04252742 · ClinicalTrials.gov registry record · Phase 4
Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine
A Phase 4 study of Migraine, sponsored by Amgen.
- Completed
- Registry status
- Phase 4
- Development phase
- 512
- Enrollment target
- 20
- Study locations
NCT04252742 is a Phase 4 study of Migraine that has completed, run by Amgen. The registered enrollment target is 512 participants, above the 353-participant average among 102 other Migraine trials with a reported enrollment target (45% higher). The trial reports 20 study locations across 8 states.
The verdict
NCT04252742, a Phase 4 study of Migraine, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 512 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to evaluate the treatment benefit of erenumab on headache duration of at least moderate pain intensity.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Erenumab
Study Locations (20)
Florida
- JEM Research Institute - Atlantis
- Jacksonville Center for Clinical Research - Jacksonville
- Visionary Investigators Network - Miami
- Renstar Medical Research - Ocala
- Heuer Medical Doctor Research LLC - Orlando
- Neurology Associates of Ormond Beach - Ormond Beach
- Visionary Investigators Network - Pembroke Pines
Colorado
- Mountain Neurological Research Center - Basalt
- Denver Neurological Clinic - Denver
- Summit Headache and Neurologic Institute - Englewood
Missouri
- StudyMetrix Research - City of Saint Peters
- Clinvest Research LLC - Springfield
- Mercy Health Research - St Louis
California
- Long Beach Clinical Trials Services Inc - Long Beach
- Clinical Research Institute, LLC - Los Angeles
Massachusetts
- Boston Clinical Trials - Boston
- New England Regional Headache Center Inc - Worcester
Idaho
- Saint Lukes Clinic - Meridian
Illinois
- Chicago Headache Center and Research Institute - Chicago
Michigan
- Michigan Head Pain and Neurological Institute - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 512 participants |
| Start Date | 2020-09-15 |
| Est. Completion | 2023-10-26 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04252742
The ClinicalTrials.gov registry entry for NCT04252742 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 512 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 353-participant average among 102 other Migraine trials with a reported enrollment target (45% higher). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04252742 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Florida, Colorado, Missouri.
Frequently Asked Questions
What is clinical trial NCT04252742 about?
NCT04252742 is a clinical study titled "Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine". The primary objective of this study is to evaluate the treatment benefit of erenumab on headache duration of at least moderate pain intensity.
What is the current status of trial NCT04252742?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 512 participants. The study started on 2020-09-15. Estimated completion is 2023-10-26.
What conditions does trial NCT04252742 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT04252742?
The interventions under investigation include: Placebo (DRUG), Erenumab (DRUG).
Who is sponsoring clinical trial NCT04252742?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04252742 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Idaho, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Headache
RECRUITING · Phase 4
-
Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications
RECRUITING · Phase 4
-
Rimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the US
RECRUITING · Phase 4
-
Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
RECRUITING · Phase 4
-
Nerivio Efficacy Under High-Frequency Use
ACTIVE NOT RECRUITING · Phase 4
-
Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45
ACTIVE NOT RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.